Related Experiment Videos
Low-molecular-weight heparin: an antithrombotic agent whose time has come
1Department of Medicine, University of Miami School of Medicine, Fla. 33101, USA.
Summary
Low-molecular-weight heparin (LMWH) combined with aspirin is recommended for early non-Q wave myocardial infarction and unstable angina. LMWH offers a cost-effective and safe alternative to unfractionated heparin (UFH) in acute coronary syndromes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) require effective anticoagulation.
- Unfractionated heparin (UFH) has been a standard treatment.
- Low-molecular-weight heparin (LMWH) has emerged as a potential alternative.
Observation:
- Clinical trials validate the benefits of LMWH in ACS.
- LMWH demonstrates cost-effectiveness compared to UFH.
- Minor bleeding, primarily injection site ecchymosis, may be more frequent with LMWH.
Findings:
- Major bleeding rates are comparable between LMWH and UFH.
- LMWH is effective in preventing pulmonary emboli, as shown in orthopedic surgery.
- LMWH should be considered for replacing UFH in ACS management.
Implications:
- LMWH offers a favorable risk-benefit profile for ACS patients.
- Cost-effectiveness of LMWH supports its wider adoption.
- Evidence supports LMWH as a preferred anticoagulant in ACS.